Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

CNBX Pharmaceuticals (CNBX) Research & Development (2016 - 2024)

CNBX Pharmaceuticals (CNBX) has disclosed Research & Development for 13 consecutive years, with -$73934.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Research & Development fell 179.3% year-over-year to -$73934.0, compared with a TTM value of -$73934.0 through May 2025, down 120.43%, and an annual FY2024 reading of $194788.0, down 54.86% over the prior year.
  • Research & Development was -$73934.0 for Q3 2024 at CNBX Pharmaceuticals, down from $49105.0 in the prior quarter.
  • Across five years, Research & Development topped out at $550842.0 in Q2 2021 and bottomed at -$73934.0 in Q3 2024.
  • Average Research & Development over 5 years is $252505.1, with a median of $263115.0 recorded in 2023.
  • Peak annual rise in Research & Development hit 769.63% in 2024, while the deepest fall reached 179.3% in 2024.
  • Year by year, Research & Development stood at $433730.0 in 2020, then rose by 1.46% to $440044.0 in 2021, then crashed by 85.71% to $62888.0 in 2022, then soared by 78.76% to $112418.0 in 2023, then crashed by 165.77% to -$73934.0 in 2024.
  • Business Quant data shows Research & Development for CNBX at -$73934.0 in Q3 2024, $49105.0 in Q2 2024, and $107199.0 in Q1 2024.